Biopharma investors, innovators, and industry executives will get an exclusive look at next-generation protein therapeutics developed by Northwestern’s top translational scientists at the fourth annual Biotech by the Lake Investor Summit on June 28, 2022, 9:00 a.m. – 12:30 p.m. (CST). The online program, jointly hosted by Chemistry of Life Processes Institute (CLP) at Northwestern and Oppenheimer and Co., will also highlight the hottest trends, grand challenges, and financing and investment insights in challenging dynamics.
Leading proteomics expert Neil Kelleher, PhD, the Walter and Mary E. Glass Professor of Molecular Biosciences at Northwestern and the Director of CLP, will open the meeting with an overview of the Human Proteoform Project, a $1.3 billion initiative to define every proteoform in the human body that will accelerate the development of more precise and effective drugs and diagnostics for disease. The project’s goal is to transform protein science through cutting-edge technology development and broad-based research collaborations.
“Protein therapeutics and the complex technology that supports their discovery are at an important inflection point,” says Kelleher. “The technology is finally catching up and making possible new breakthroughs that used to be difficult and time-consuming to pursue. This is an exciting time for proteomics, especially at Northwestern where our proteomics team partners closely with clinicians and scientists to better understand the precise role of proteins in disease.”
Northwestern faculty members Shana Kelley, PhD (Chemistry) – “Rare Cell Profiling for Therapeutic Discovery and Development”; Elizabeth McNally, MD, PhD (Genetic Medicine) – “Using Genetic Signals to Develop New Protein Biologics for Muscle Disease”; Peter Penzes, PhD (Psychiatry and Behavioral Sciences) – “Small-Molecule Kalirin Antagonists for the Treatment of Chronic Neuropathic Pain and Other Conditions”; and Samuel Stupp, PhD (Chemistry) – “Supramolecular Peptide Medicines” will present their latest research in protein therapeutics.
Pharmaceutical industry leaders Arvind Rajpal, PhD, Vice President Large Molecule Drug Discovery – Antibody Engineering & Protein Chemistry, Genentech, and Alan Russell, PhD, Vice President, Biologics, Amgen, will provide insights on next-generation antibody therapeutics and solving the grand challenges of protein therapeutics.
Industry experts Karen Tkach Tuzman, PhD, Senior Editor, Head of Discovery and Preclinical Development, BioCentury Inc., Ginger S. Johnson, PhD, President, Commercial BioConsulting, Lumanity, Parag Mallick, PhD, Associate Professor (Research) of Radiology at Stanford and Founder and Chief Scientist, Nautilus Biotechnology and Vini Mani, PhD,
Head of Platform at ProFound Therapeutics will participate in the program’s hot topics panel and Jay Olson, CFA, Research Analyst, Oppenheimer & Co, will lead the biotech financing and investing panel that will include Margarita Chavez, JD, Managing Director at AbbVie Ventures, Stefan Loren, PhD, Managing Director, Life Sciences, Oppenheimer & Co., Scott Morenstein, Managing Director, BAAM – New York at Blackstone and William Slattery, Partner at Deerfield.
The meeting is free and open to investors, asset managers, research analysts, industry members, and biotech innovators.
Register for the event.
View the latest agenda and speakers.
Download the program.
Read Oppenheimer’s Report on Biotech by the Lake 2021: Targeting Neurological Disorders.